A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY TREET; LIBERTY-EoE-TREET
- Sponsors Regeneron Pharmaceuticals
- 26 Feb 2024 Results of subgroup analysis assessing the efficacy of dupilumab, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 09 Feb 2024 According to a Sanofi media release, positive dupixent data on histologic, symptomatic, and endoscopic aspects of EoE in adults and adolescents up to 52 weeks, regardless of prior elimination diet or food allergy will be presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting from February 23 to 26.
- 27 Nov 2023 Results of sub-group analysis assessing the effect of long-term dupilumab on histological, symptomatic and endoscopic aspects of eosinophilic oesophagitis (EoE) in adolescent and adult patients with and without prior use of swallowed topical corticosteroids (STC) or prior inadequate response, intolerance or contraindication to swallowed topical corticosteroids, published in the Gut